Skip to main content
OpenTrials
Completed

NCT Number: NCT01872546

Skin Transcriptional Profiles In Psoriatic Patients Under Adalimumab Biotherapy

The expertise in the characterization of transcriptomics profile in lesional psoriatic skin and on the availability of innovative therapy for these patients.The investigators propose to follow the modification of the skin transcriptomics profile in psoriatic patients during successful Adalimumab biotherapy. Skin transcriptomics profiles of normal skin, psoriatic non lesional skin, and psoriatic lesional skin before and after biotherapy will be compared. The investigators will focus on the modification of the cytokine "signature" in these skin lesions and of some markers of keratinocyte inflammation. The modification of the transcriptomics profile induced by the biotherapy will be correlated to the clinical response Psoriasis Area and Severity Index.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Plaque Psoriasis

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Chu Poitiers

Poitiers, 86021, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults with chronic plaque psoriasis involving at least 10% of body surface area with no previous biotherapy.
  • Adalimumab prescribed in usual practice

Exclusion criteria

  • Patients presenting a contraindication to the use of Adalimumab: hypersensibility in Adalimumab or in one of the excipients.
  • Patients presenting an evolutionary tuberculosis or the other severe infections such as sepsis and opportunist infections.
  • Patients with one cardiac insufficiencies moderated in severe.
  • Patients under anakinra or abatacept.
  • Patients with a current participation in another study of clinical research.

Treatment and study plan

Adalimumab Every Week

Drug

Adalimumab was administered subcutaneously at a dose of 80 mg at Week 0 and 40 mg every other week starting from Week 1 to Week 16.

Primary outcomes

  1. Area and Severity Index (PASI)

    Time frame: 4 weeks

    Number of patients with a reduction in PASI score at 4 weeks

Secondary outcomes

  1. Dermatology Life Quality Index (DLQI) Scores

    Time frame: 4 weeks

    Number of patients with a reduction in DLGI score at 4 weeks

Sponsors and collaborators

Lead sponsor

Poitiers University Hospital

Other

Registry information

Official study title

Characterization of Skin Th17 Transcriptional Profiles in Psoriatic Patients Under Adalimumab Biotherapy

Acronym: CYTOPSO

Important dates

Study start
2013
Primary completion
2013
Study completion
2013
First posted
Jun 7, 2013
Registry last updated
Jun 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.